On March 14, 2019 Health Canada released a MedEffect Notice advising of an additional recall of two lots of irbesartan tablets dispensed in Quebec sourced from Teva API India Ltd. This is the first notice we have seen that isolates Quebecois patients as those affected by these tainted sartan drugs. This is the latest in an ongoing series of MedEffects detailing recalls of sartan drugs due to nitrosamine contamination from N-nitrosodiethylamine (NDEA). Canada has seen recalls since July 2018 indicating the presence of known carcinogen N-nitrosodimethylamine (NDMA) and probable carcinogen NDEA in products used to manage cardiovascular symptoms related to high blood pressure, stroke, heart failure and heart attack.
